Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Health Care M&Deals, Week Ending February 15, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day, in the quarterly report. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price AbbVie, Inc. Commercialization and development rights for TNB-383B $90,000,000 Labs, MRI & Dialysis Acquirer Target Price RadNet, Inc. Kern Radiology Medical Group, Inc. N/A Private investor group U.S. Renal Care, Inc. N/A Long-Term Care Acquirer... Read More »
Dubai Investments Buys Back Stake of Globalpharma from Sanofi
Dubai Investments (DFM: DIC) announced last week that it will purchase an additional 66% stake in pharmaceutical company Globalpharma, giving it full ownership of the company. Dubai Investments invest in a number of sectors, including healthcare and education in the UAE and the Middle East. You’re not alone if this story sounds familiar. Sanofi (NASDAQ: SNY) purchased a 66% majority stake of Globalpharma from Dubai Investments in 2014, leaving the latter company only a 34% minority stake up until last week’s deal. Globalpharma manufactures and commercializes generic medicines, and Sanofi integrated Globalpharma as its platform to manufacture and promote the generics portfolio... Read More »
GlaxoSmithKline builds immunotherapy pipeline with new collaboration
GlaxoSmithKline plc (NYSE: GSK) (GSK) has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany to study M7824, an investigational bifunctional fusion protein immunotherapy that is currently in clinical development for multiple difficult-to-treat cancers. Under the terms of the agreement, GSK will pay Merck KGaA $342.3 million (€300 million) upfront. Merck KGaA is also eligible for up to $3.31 billion (€2.9 billion) in milestone payments. The potential deal value could amount to $4.23 billion (€3.7 billion). Both companies will jointly conduct development and commercialization with all profits and costs from the collaboration being shared equally on a global basis.... Read More »
Health Care M&A Deals, Week Ending February 8, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day, in the quarterly report. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price GlaxoSmithKline plc Collaboration on M7824 $342.3 million Cullinan Pearl License to TAS6417 N/A Galapagos NV Collaboration on fibrotic disease therapies N/A Genentech, Inc. Global rights to IL-15 cytokine therapeutics $120,000,000 eHealth... Read More »
Healthcare Deal Volume Got a Jump Start in January
January was a fairly busy month for healthcare M&A. Preliminary data shows 133 deals reported, nearly equal to December’s 136. The momentum coming out of the fourth quarter spilled into the new year and even without a big boost in deal announcements from the J.P. Morgan Healthcare Conference, consolidation in the industry seems to be going full steam ahead. And yet. Compared with the 151 deals announced a year ago, M&A is off by 12%. Granted, we don’t see that many deals on a monthly basis, which makes for a hard comp here. But as we swing into February, deal flow has slowed noticably. It could be temporary, as investors take stock of the economic and political landscape and... Read More »
Hospital M&A: Bigger Isn’t Always Better
That was the week that was. Two huge hospital mergers came to an end, one successfully and the other, not. In announcing the end results, CEOs involved in those deals each emphasized their goal was not about “getting bigger,” but to deliver better health care to more patients. Seriously, what CEO is going to say they just need more facilities to boost the bottom line and don’t care about patients? First, the deal that crossed the finish line. For 15 months, Catholic Health Initiatives and Dignity Health negotiated the details of the definitive agreement they signed in December 2017. The deal closed on February 1, creating one of the largest not-for-profit health systems in the country with... Read More »
Health Care M&A Deals, Week Ending February 1, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day, in the quarterly report. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Aldeyra Therapeutics, Inc. Helio Vision, Inc. $10,000,000 Neurocrine Biosciences, Inc. Rights to four gene therapy programs $165,000,000 Janssen Pharmaceuticals, Inc. Rights to retinal disease treatments $100,000,000 Tetra Bio-Pharma Panag... Read More »
Medical Device Makers Upgrade with Digital Health Deals
This week BioTelemetry, Inc. (NASDAQ: BEAT) purchased Geneva Healthcare, Inc. for $45 million, continuing the 2018 trend of medical device companies acquiring digital health groups. BioTelemetry provides cardiac monitoring device manufacturing and monitoring and wanted Geneva’s proprietary cloud-based platform. Its technology aggregates data from device manufacturers’ systems, enabling a company to remotely monitor a patient’s implantable cardiac devices such as pacemakers, defibrillators and loop recorders. Geneva’s platform provides physicians with a single portal to order patient monitoring, view monitoring results and request routine device checks.... Read More »
Healthscope Changes Hands Again
Healthscope Ltd. (ASX: HSO), Australia’s second largest private hospital chain, is being sold once again, this time for $4.14 billion, or 1.8x revenue. The Melbourne, Victoria-based company owns 43 hospitals across all states in Australia and is the largest pathology services provider in New Zealand, with 24 laboratories. Three buyers are involved, two of them real estate investment trusts (REITs). First, Brookfield Business Partners LP (NYSE: BBU), a subsidiary of Brookfield Asset Management Inc. (NYSE: BAM), will acquire 100% of Healthscope’s shares, priced at $1.81 (AU$2.50) per share. That returns approximately $1.0 billion in equity. The remainder will be paid with $1.4... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
